APR 05, 2022 10:00 AM PDT

Alzheimer's Drug May improve Symptoms of Down Syndrome

WRITTEN BY: Annie Lennon

A protein named GM-CSF used to treat Alzheimer's disease improves cognitive function in mice with Down syndrome (DS). The corresponding research was conducted by a team of scientists at the University of Colorado Anschutz Medical Campus and published in the journal Neurobiology of Disease.

GM-CSF is a natural human protein that has been used safely and effectively for over 30 years under the drug name 'sargramostim'. Studies have shown that GM-CSF improves neurological symptoms associated with Alzheimer's disease (AD). 

People with DS are at higher risk for AD, with most developing symptoms of dementia by age 60. The current study examines if GM-CSF could be repurposed to treat the neurological symptoms in DS that precede dementia.

The researchers used a mouse model of DS to run their experiment. They gave the treatment to a group of mice with DS and a healthy group, while a control group was given saline. The mice underwent learning and memory tests, such as solving mazes, before and after treatment.

The researchers found that the drug had pro-inflammatory and anti-inflammatory properties and that it helped regulate the immune system. It also improved learning and memory deficits and helped to regenerate certain nerve cells in the mice with DS, as well as improve cognition in mice without the illness. 

The results are unexpected as GM-CSF has pro-inflammatory properties, say the researchers. This challenges the theory that symptoms of AD and DS may be due to chronic inflammation and indicates that further research into the mechanisms of neurological decline in these conditions is necessary.

The researchers noted some limitations to the study. The exact mechanism by which GM-CSF improves the cognitive function of the mice could not be determined due to the complex and not yet understood effects of the compound on the immune and nervous systems. Furthermore, DS in mice presents differently from in humans, so the results may not translate over.

The results nevertheless indicate that "sargramostim should be tested for safety, tolerability, and efficacy for improving cognition in people with Down syndrome", write the researchers. 

Scientists at CU Medical Campus and Colorado State University are currently researching the drug's potential to treat young adults with DS regarding cognitive function, quality of life measures, and biomarkers associated with neuronal damage.

 

Sources: ScienceDailyNeurobiology of Disease

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
OCT 12, 2022
Plants & Animals
New Antimicrobial Discovered in Bacteria That Infects Potatoes
OCT 12, 2022
New Antimicrobial Discovered in Bacteria That Infects Potatoes
Resistance to antibiotics and antimicrobials has become an increasingly common concern around the globe. Due to high rat ...
OCT 19, 2022
Health & Medicine
Study Reveals Retained Dust in Lungs of Military Personnel
OCT 19, 2022
Study Reveals Retained Dust in Lungs of Military Personnel
Researchers from the U.S. Geological Survey (USGS) and National Jewish Health teamed up to investigate lung disease seen ...
NOV 08, 2022
Drug Discovery & Development
Blood Pressure Drug May Reduce Alzheimer's Risk in Black People
NOV 08, 2022
Blood Pressure Drug May Reduce Alzheimer's Risk in Black People
Telmisartan, a blood pressure-lowering medication, may help prevent or treat Alzheimer's disease (AD) in Black indiv ...
NOV 25, 2022
Drug Discovery & Development
Antibiotics for Acne May Impair Bone Development in Teens
NOV 25, 2022
Antibiotics for Acne May Impair Bone Development in Teens
Long-term antibiotic use to treat adolescent acne disrupts the gut microbiome and impairs bone maturation. The correspon ...
NOV 28, 2022
Drug Discovery & Development
Experimental Drug Lowers 'Bad' Cholesterol by 70%
NOV 28, 2022
Experimental Drug Lowers 'Bad' Cholesterol by 70%
An experimental orally-administered drug reduces 'bad cholesterol' in mice by 70%. The corresponding research wa ...
DEC 01, 2022
Drug Discovery & Development
The Impact of AI on Drug Discovery
DEC 01, 2022
The Impact of AI on Drug Discovery
Artificial Intelligence, also known as “AI”, has been the talk of the past year. AI performs and responds to ...
Loading Comments...